Sendak, M., M. C. Elish, M. Gao, J. Futoma, W. Ratliff, M. Nichols, A. Bedoya, S. Balu, and C. O’Brien. ““The human body is a black box”: Supporting clinical decision-making with deep learning.” In Fat* 2020 Proceedings of the 2020 Conference on Fairness, Accountability, and Transparency, 99–109, 2020. https://doi.org/10.1145/3351095.3372827.
Rhee, Chanu, Travis M. Jones, Yasir Hamad, Anupam Pande, Jack Varon, Cara O’Brien, Deverick J. Anderson, et al. “Prevalence, Underlying Causes, and Preventability of Sepsis-Associated Mortality in US Acute Care Hospitals.” Jama Netw Open 2, no. 2 (February 1, 2019): e187571. https://doi.org/10.1001/jamanetworkopen.2018.7571.
Bedoya, Armando D., Meredith E. Clement, Matthew Phelan, Rebecca C. Steorts, Cara O’Brien, and Benjamin A. Goldstein. “Minimal Impact of Implemented Early Warning Score and Best Practice Alert for Patient Deterioration.” Crit Care Med 47, no. 1 (January 2019): 49–55. https://doi.org/10.1097/CCM.0000000000003439.
Rhee, Chanu, Michael R. Filbin, Anthony F. Massaro, Amy L. Bulger, Donna McEachern, Kathleen A. Tobin, Barrett T. Kitch, et al. “Compliance With the National SEP-1 Quality Measure and Association With Sepsis Outcomes: A Multicenter Retrospective Cohort Study.” Crit Care Med 46, no. 10 (October 2018): 1585–91. https://doi.org/10.1097/CCM.0000000000003261.
Rhee, Chanu, Sarah R. Brown, Travis M. Jones, Cara O’Brien, Anupam Pande, Yasir Hamad, Amy L. Bulger, et al. “Variability in determining sepsis time zero and bundle compliance rates for the centers for medicare and medicaid services SEP-1 measure.” Infect Control Hosp Epidemiol 39, no. 8 (August 2018): 994–96. https://doi.org/10.1017/ice.2018.134.
Chudgar, Saumil, William C. McManigle, Aubrey Jolly Graham, Jonathan Bae, Noppon P. Setji, and Cara L. O’Brien. “TEACHING ESSENTIAL SKILLS: TRAINING MEDICAL STUDENTS IN QUALITY IMPROVEMENT, PROCEDURES, AND TRANSITIONS OF CARE.” In Journal of General Internal Medicine, 28:S480–S480. SPRINGER, 2013.
Perret-Guillaume, Christine, and Denis Wahl. “Cost-effectiveness of ximelagatran for stroke prevention.” Jama 293, no. 23 (June 15, 2005): 2860–61. https://doi.org/10.1001/jama.293.23.2860.
“Cost-effectiveness of Ximelagatran for Stroke Prevention—Reply.” Jama 293, no. 23 (June 15, 2005): 2860–2860. https://doi.org/10.1001/jama.293.23.2861-a.
O’Brien, Cara L., and Brian F. Gage. “Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation.” Jama 293, no. 6 (February 9, 2005): 699–706. https://doi.org/10.1001/jama.293.6.699.
Brendza, Robert P., Cara O’Brien, Kelly Simmons, Daniel W. McKeel, Kelly R. Bales, Steven M. Paul, John W. Olney, Joshua R. Sanes, and David M. Holtzman. “PDAPP; YFP double transgenic mice: a tool to study amyloid-beta associated changes in axonal, dendritic, and synaptic structures.” J Comp Neurol 456, no. 4 (February 17, 2003): 375–83. https://doi.org/10.1002/cne.10536.